Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis
Alex Castañeda-Sabogal, Diego Chambergo‐Michilot, Carlos J. Toro‐Huamanchumo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19

Showing 19 citing articles:

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Andrew Bryant, Theresa A Lawrie, Therese Dowswell, et al.
American Journal of Therapeutics (2021) Vol. 28, Iss. 4, pp. e434-e460
Open Access | Times Cited: 232
COVID‐19: immunopathology, pathophysiological mechanisms, and treatment options
Larissa E. van Eijk, Mathijs Binkhorst, Arno R. Bourgonje, et al.
The Journal of Pathology (2021) Vol. 254, Iss. 4, pp. 307-331
Open Access | Times Cited: 125
Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Yuani M. Roman, Paula Alejandra Burela, Vinay Pasupuleti, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 6, pp. 1022-1029
Open Access | Times Cited: 107
Prophylaxis against covid-19: living systematic review and network meta-analysis
Jessica Bartoszko, Reed Siemieniuk, Elena Kum, et al.
BMJ (2021), pp. n949-n949
Open Access | Times Cited: 104
Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
Yuani M. Roman, Paula Alejandra Burela, Vinay Pasupuleti, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 32
Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia
Jorge Enrique Machado‐Alba, Luis Fernando Valladales‐Restrepo, Manuel Enrique Machado‐Duque, et al.
PLoS ONE (2021) Vol. 16, Iss. 11, pp. e0260169-e0260169
Open Access | Times Cited: 22
In a life full of risks, COVID-19 makes little difference. Responses to COVID-19 among mobile migrants in gold mining areas in Suriname and French Guiana
Marieke Heemskerk, François‐Michel Le Tourneau, Hélène Hiwat, et al.
Social Science & Medicine (2022) Vol. 296, pp. 114747-114747
Open Access | Times Cited: 15
Identification and Development of Therapeutics for COVID-19
Halie M. Rando, Nils Wellhausen, Soumita Ghosh, et al.
mSystems (2021) Vol. 6, Iss. 6
Open Access | Times Cited: 19
Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial
Ananda Wijewickrema, Hasini Banneheke, A. Pathmeswaran, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
An Updated Systematic Review and Meta-Analysis of Mortality, Need for ICU admission, Use of Mechanical Ventilation, Adverse effects and other Clinical Outcomes of Ivermectin Treatment in COVID-19 Patients
Smruti Karale, Vikas Bansal, Janaki Makadia, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 15
COVID-19 signalome: Potential therapeutic interventions
Kenneth Lundström, Altijana Hromić‐Jahjefendić, Esma Bilajac, et al.
Cellular Signalling (2022) Vol. 103, pp. 110559-110559
Open Access | Times Cited: 11
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Steven G. Rothrock, Kurt Weber, Philip Giordano, et al.
American Journal of Therapeutics (2021) Vol. 29, Iss. 1, pp. e87-e94
Open Access | Times Cited: 11
Ivermectin for prevention and treatment of COVID-19 infection: a systematic review and meta-analysis
Andrew Bryant, Theresa A Lawrie, Therese Dowswell, et al.
(2021)
Closed Access | Times Cited: 9
Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?
Mark J. Siedner
Open Forum Infectious Diseases (2021) Vol. 8, Iss. 11
Open Access | Times Cited: 6
Ivermectin for Prevention and Treatment of COVID-19 Infection: a Systematic Review and Meta-analysis
Andrew Bryant, Theresa A Lawrie, Therese Dowswell, et al.
Research Square (Research Square) (2021)
Closed Access | Times Cited: 4
Ivermectin in COVID-19 Management: What is the Current Evidence?
Madhavi Eerike, Gerard Marshall Raj, Rekha Priyadarshini, et al.
Infectious Disorders - Drug Targets (2022) Vol. 22, Iss. 4
Closed Access | Times Cited: 1
Ivermectin in the Prophylaxis and Treatment of Patients with SARS-CoV-2: A Living Systematic Review and Meta-Analysis
René Rodríguez‐Gutiérrez, Karina Raygoza-Cortez, Mariana García-Leal, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 1
Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic
Kenneth Lundström
Elsevier eBooks (2022), pp. 205-226
Closed Access
Polémica en tiempos del COVID-19: ¿es la ivermectina útil para su tratamiento o prevención?
Víctor Soto-Cáceres
Revista Experiencia en Medicina del Hospital Regional Lambayeque (2021) Vol. 7, Iss. 2
Open Access
Page 1

Scroll to top